Small loss on Københavns Fondsbørs Wednesday

The market showed a small loss Wednesday, and OMX Copenhagen 25 GI (OMXC25GI) ended the day at 1240 points, which is a decline of 0.62 percent.

52 shares were up and 81 were down, while 14 remained unchanged, and there was no trading in 11 shares.

Total value of the trading volume for shares and primary capital certificates Wednesday was approximately 6.0 billion.

Össur hf. (OSSR) developed negatively and fell 1.43 percent to a close of 41.25 kroner. The stock thereby reversed down after 11 days of gains. The stock is trend wise positive in the medium term.
ISS (ISS) closed at 102 kroner after a small gain of 0.84 percent. This past week the stock has gained as much as 10.47 percent. Technically, however, it does not look good. The stock is trend wise negative in the medium term and a further decline is indicated.
Genmab (GMAB) showed a flat development and ended the day at 1465 kroner (+0.21 percent). The stock has now closed up for the fifth day in a row. Technically it also looks good. The stock is trend wise positive in the medium term, has broken up through the resistance at 1420 kroner and a further increase is indicated.
NNIT (NNIT) ended with a solid gain of 3.34 percent and closed at 111 kroner. This past week the stock has gained as much as 28.64 percent. The stock is trend wise negative in the medium term.
Jeudan (JDAN) closed at 1130 kroner after posting a loss of 2.16 percent. This past week the stock has lost as much as 4.64 percent. Technically, however, it looks good. The stock is trend wise positive in the medium term and a further increase is indicated.

Losers Wednesday

Odico-6.93%
Scandinavian Brake Systems-6.25%
Bang & Olufsen Holding-4.98%
Rias B-4.93%
TORM A-4.30%

Most traded Wednesday

Novo Nordisk B1361.47
Coloplast B440.86
Vestas Wind Systems365.67
Danske Bank302.59
Ørsted289.71
 


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.

Titlex

OK